Synthesis and immunological activities of novel agonists of toll-like receptor 9

Cellular Immunology

Volumn 263, Issue 1, 2010, Pages 105-113

  Struthers, Mary ^a   Bett, Andrew J ^b   Wisniewski, Thomas ^a   Dubey, Sheri A ^b   Precopio, Melissa ^c   Jiang, Weiwen ^c   Sun, Zhenhua ^c   Wang, Hao ^c   Nowak, Ireneusz ^c   Putta, Mallikarjuna R ^c   Yu, Dong ^c   Tang, Jimmy X ^c   Kandimalla, Ekambar R ^c   Agrawal, Sudhir ^c   Casimiro, Danilo R ^b  

^a Merck Research Labratories   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c HYBRIDON INC   (United States)

Author keywords

Immune stimulatory; Oligodeoxynucleotides; T helper 1 type immune response; Toll like receptor 9

Indexed keywords

ALPHA INTERFERON; IMMUNE MODULATORY OLIGONUCLEOTIDE; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; UPREGULATION;

ANIMALS; B-LYMPHOCYTES; CELL LINE; CELL PROLIFERATION; DENDRITIC CELLS; FEMALE; HUMANS; INTERFERON-ALPHA; LYMPHOCYTE ACTIVATION; MACACA MULATTA; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDES; PYRIMIDINONES; THIAZOLES; TOLL-LIKE RECEPTOR 9;

MACACA MULATTA; MUS;

EID: 77952541603     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2010.03.005     Document Type: Article

References (53)

1. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
2. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S. A toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
3. Agrawal S., Kandimalla E.R. Synthetic agonists of toll-like receptors 7, 8 and 9. Biochem. Soc. Trans. 2007, 35:1461-1467.
4. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. USA 1996, 93:2879-2883.
5. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002, 20:709-760.
6. Messina J.P., Gilkeson G.S., Pisetsky D.S. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J. Immunol. 1991, 147:1759-1764.
7. Tokunaga T., Yamamoto H., Shimada S., Abe H., Fukuda T., Fujisawa Y., Furutani Y., Yano O., Kataoka T., Sudo T., et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Nat. Cancer Inst. 1984, 72:955-962.
8. Zhao Q., Temsamani J., Zhou R.Z., Agrawal S. Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 1997, 7:495-502.
9. J.J. Hwang, S. Park, A. Amin, R.R. Martin, T. Sullivan, T. Burns, S. Agrawal, M.J Waxdal, S. Malik, J.L. Marshall, A phase I study of HYB2055 in patients (pts) with advanced solid malignancies, J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings, 22, 14S (Supplement), 2004, p. 3111.
10. D.J. Moore, J. Hwang, J. McGreivy, S. Park, S. Malik, R.R. Martin, T.M. Sullivan, S. Agrawal, J. Marshall, A phase I trial of escalating doses of the TLR9 agonist HYB2055 in patients with advanced solid tumors, J. Clin, Oncol., 2004 ASCO Annual Meeting Proceedings, 23, 16S part I of II (Supplement), 2005, p. 2503.
11. T. Kuzel, J. Dutcher, S. Ebbinghaus, M. Gordon, S. Grubbs, K. Khan, A. Lipton, D. McDermott, F. Millard, D. Quinn, T. Sullivan, A phase 2 multicenter, randomized, open-label study of two dose levels of IMO-2055 in patients with metastatic or recurrent renal cell carcinoma, Presented at the 8th International Kidney Cancer Symposium, September 25-26, 2009, Chicago, Il, USA.
12. D. Smith, P. Conkling, D. Richards, C. Alemany, T. Boyd, L. Garbo, D. Loesch, D. Wages, A. Bexon, J. Murphy. Phase 1 study of the toll-like receptor 9 (TLR9) agonist, IMO-2055, combined with erlotinib and bevacizumab in patients with advanced or metastatic non-small cell lung cancer. Presented at the 15th ECCO and 34th ESMO Multidisciplinary Congress, September 20-24, 2009, Berlin, Germany.
13. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Krieg A.M., Li Y., Laframboise C., Al Adhami M.J., Khaliq Y., Seguin I., Cameron D.W. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004, 22:3136-3143.
14. Halperin S.A., Dobson S., McNeil S., Langley J.M., Smith B., McCall-Sani R., Levitt D., VanNest G., Gennevois D., Eiden J.J. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a clicensed hepatitis B vaccine in healthy young adults. Vaccine 2006, 24:20-26.
15. Mchutchison J.G., Bacon B.R., Gordon S.C., Lawitz E., Shiffman M., Afdhal N.H., Jacobson I.M., Muir A., Al-Adhami M., Morris M.L., Lekstrom-Himes J.A., Efler S.M., Davis H.L. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 2007, 46:1341-1349.
16. Pashenkov M., Goess G., Wagner C., Hormann M., Jandl T., Moser A., Britten C.M., Smolle J., Koller S., Mauch C., Tantcheva-Poor I., Grabbe S., Loquai C., Esser S., Franckson T., Schneeberger A., Haarmann C., Krieg A.M., Stingl G., Wagner S.N. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin Oncol. 2006, 24:5716-5724.
17. Tulic M.K., Fiset P.-O., Christodoulopoulos P., Vaillancourt P., Desrosiers M., Lavigne F., Eiden J., Hamid Q. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J. Allergy Clin. Immunol. 2004, 113:235-241.
18. Cong Y.P., Song S.S., Bhagat L., Pandey R.K., Yu D., Kandimalla E.R., Agrawal S. Self-stabilized CpG DNAs optimally activate human B cells and plasmacytoid dendritic cells. Biochem. Biophy. Res. Commun. 2003, 310:1133-1139.
19. Kandimalla E.R., Bhagat L., Cong Y.P., Pandey R.K., Yu D., Zhao Q., Agrawal S. Secondary structures in CpG oligonucleotides affect immunostimulatory activity. Biochem. Biophy. Res. Commun. 2003, 306:948-953.
20. Yu D., Putta M.R., Bhagat L., Dai M., Wang D., Trombino A.F., Sullivan T., Kandimalla E.R., Agrawal S. Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction. Antimicrob. Agents Chemother. 2008, 52:4320-4325.
21. Zhao Q., Temsamani J., Iadarola P.L., Jiang Z., Agrawal S. Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem. Pharmacol. 1996, 51:173-182.
22. Zhao Q., Yu D., Agrawal S. Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity. Bioorg. Med. Chem. Lett. 1999, 9:3453-3458.
23. Zhao Q., Yu D., Agrawal S. Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside. Bioorg. Med. Chem. Lett. 2000, 10:1051-1054.
24. Yu D., Kandimalla E.R., Zhao Q., Cong Y., Agrawal S. Immunostimulatory properties of phosphorothioate CpG DNA containing both 3′,5′- and 2′,5′-internucleotide linkages. Nucleic Acids Res. 2002, 30:1613-1619.
25. Agrawal S., Kandimalla E.R. Antisense and/or immunostimulatory oligonucleotide therapeutics. Curr. Cancer Drug Targets 2001, 1:197-209.
26. Yu D., Kandimalla E.R., Zhao Q., Cong Y., Agrawal S. Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages. Bioorg. Med. Chem. 2001, 9:2803-2808.
27. Yu D., Kandimalla E.R., Zhao Q., Cong Y., Agrawal S. Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases. Bioorg. Med. Chem. Lett. 2001, 11:2263-2267.
28. Yu D., Kandimalla E.R., Zhao Q., Bhagat L., Cong Y., Agrawal S. Requirement of nucleobase proximal to CpG dinucleotide for immunostimulatory activity of synthetic CpG DNA. Bioorg. Med. Chem. 2003, 11:459-464.
29. Yu D., Kandimalla E.R., Cong Y., Tang J., Tang J.Y., Zhao Q., Agrawal S. Design, synthesis, and immunostimulatory properties of CpG DNAs containing alkyl-linker substitutions: role of nucleosides in the flanking sequences. J. Med. Chem. 2002, 45:4540-4548.
30. Kandimalla E.R., Yu D., Zhao Q., Agrawal S. Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships. Bioorg. Med. Chem. 2001, 9:807-813.
31. Yu D., Putta M.R., Bhagat L., Li Y., Zhu F., Wang D., Tang J.X., Kandimalla E.R., Agrawal S. Agonists of toll-like receptor 9 containing synthetic dinucleotide motifs. J. Med. Chem. 2007, 50:6411-6418.
32. Putta M.R., Zhu F., Li Y., Bhagat L., Cong Y., Kandimalla E.R., Agrawal S. Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications. Nucleic Acids Res. 2006, 34:3231-3238.
33. Kandimalla E.R., Bhagat L., Li Y., Yu D., Wang D., Cong Y.P., Song S.S., Tang J.X., Sullivan T., Agrawal S. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2′-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists. Proc. Natl. Acad. Sci. USA 2005, 102:6925-6930.
34. Kandimalla E.R., Bhagat L., Zhu F.G., Yu D., Cong Y.P., Wang D., Tang J.X., Tang J.Y., Knetter C.F., Lien E., Agrawal S. A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proc. Natl. Acad. Sci. USA 2003, 100:14303-14308.
35. Yu D., Zhao Q., Kandimalla E.R., Agrawal S. Accessible 5′-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity. Bioorg. Med. Chem. Lett. 2000, 10:2585-2588.
36. Kandimalla E.R., Bhagat L., Yu D., Cong Y., Tang J., Agrawal S. Conjugation of ligands at the 5′-end of CpG DNA affects immunostimulatory activity. Bioconjug. Chem. 2002, 13:966-974.
37. Yu D., Kandimalla E.R., Bhagat L., Tang J.Y., Cong Y., Tang J., Agrawal S. 'Immunomers'-novel 3′,3′-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res. 2002, 30:4460-4469.
38. Yu D., Zhu F.G., Bhagat L., Wang H., Kandimalla E.R., Zhang R., Agrawal S. Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem. Biophy. Res. Commun. 2002, 297:83-90.
39. Bhagat L., Zhu F.G., Yu D., Tang J., Wang H., Kandimalla E.R., Zhang R., Agrawal S. CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents. Biochem. Biophy. Res. Commun. 2003, 300:853-861.
40. Kandimalla E.R., Bhagat L., Wang D., Yu D., Zhu F.G., Tang J., Wang H., Huang P., Zhang R., Agrawal S. Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res. 2003, 31:2393-2400.
41. Agrawal D.K., Edwan J., Kandimalla E.R., Yu D., Bhagat L., Wang D., Agrawal S. Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma. Int. Immunopharmacol. 2004, 4:127-138.
42. Krieg A.M. Therapeutic potential of toll-like receptor 9 activation. Nat. Rev. 2006, 5:471-484.
43. Abel K., Wang Y., Fritts L., Sanchez E., Chung E., Fitzgerald-Bocarsly P., Krieg A.M., Miller C.J. Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells. Clin. Diagn. Lab. Immunol. 2005, 12:606-621.
44. Rothenfusser S., Tuma E., Endres S., Hartmann G. Plasmacytoid dendritic cells: the key to CpG. Hum. Immunol. 2002, 63:1111-1119.
45. Wille-Reece U., Flynn B.J., Lore K., Koup R.A., Kedl R.M., Mattapallil J.J., Weiss W.R., Roederer M., Seder R.A. HIV Gag protein conjugated to a toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc. Natl. Acad. Sci. USA 2005, 102:15190-15194.
46. Stewart V.A., McGrath S., Krieg A.M., Larson N.S., Angov E., Smith C.L., Brewer T.G., Heppner D.G. Activation of innate immunity in healthy Macaca mulatta macaques by a single subcutaneous dose of GMP CpG 7909: safety data and interferon-inducible protein-10 kinetics for humans and macaques. Clin. Vaccine Immunol. 2008, 15:221-226.
47. Pashenkov M., Goess G., Wagner C., Hormann M., Jandl T., Moser A., Britten C.M., Smolle J., Koller S., Mauch C., Tantcheva-Poor I., Grabbe S., Loquai C., Esser S., Franckson T., Schneeberger A., Haarmann C., Krieg A.M., Stingl G., Wagner S.N. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin. Oncol. 2006, 24:5716-5724.
48. McHutchison J.G., Bacon B.R., Gordon S.C., Lawitz E., Shiffman M., Afdhal N.H., Jacobson I.M., Muir A., Al-Adhami M., Morris M.L., Lekstrom-Himes J.A., Efler S.M., Davis H.L. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 2007, 46:1341-1349.
49. Krieg A.M., Efler S.M., Wittpoth M., Al Adhami M.J., Davis H.L. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J. Immunother. 2004, 27:460-471.
50. Ida J.A., Shrestha N., Desai S., Pahwa S., Hanekom W.A., Haslett P.A. A whole blood assay to assess peripheral blood dendritic cell function in response to toll-like receptor stimulation. J. Immunol. Methods 2006, 310:86-89.
51. Liu Y.J. IPC: Professional Type I interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 2005, 23:275-306.
52. Fanning S.L., George T.C., Feng D., Feldman S.B., Megjugorac N.J., Izaguirre A.G., Fitzgerald-Bocarsly P. Receptor cross-linking on human plasmacytoid dendritic cells leads to the regulation of IFN-alpha production. J. Immunol. 2006, 177:5829-5839.
53. Gary-Gouy H., Lebon P., Dalloul A.H. Type I interferon production by plasmacytoid dendritic cells and monocytes is triggered by viruses, but the level of production is controlled by distinct cytokines. J. Interferon Cytokine Res. 2002, 22:653-659.